Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.

Shahidi M, Tay ES, Read SA, Ramezani-Moghadam M, Chayama K, George J, Douglas MW.

J Gen Virol. 2014 Nov;95(Pt 11):2468-79. doi: 10.1099/vir.0.067231-0. Epub 2014 Jul 22.

PMID:
25053565
2.

Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication.

Sun LJ, Yu JW, Wan L, Zhang XY, Shi YG, Chen MY.

Int J Infect Dis. 2014 Jun;23:75-81. doi: 10.1016/j.ijid.2013.12.017. Epub 2014 Apr 2.

3.

2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinase.

Yang D, Xue B, Wang X, Yu X, Liu N, Gao Y, Liu C, Zhu H.

PLoS One. 2013 May 31;8(5):e64932. doi: 10.1371/journal.pone.0064932. Print 2013.

4.

Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes.

Toyoda M, Kitaoka A, Machida K, Nishinakagawa T, Yada R, Kohjima M, Kato M, Kotoh K, Sakamoto N, Shiota G, Nakamuta M, Nakashima M, Enjoji M.

Int J Mol Med. 2011 May;27(5):619-24. doi: 10.3892/ijmm.2011.622. Epub 2011 Feb 17.

PMID:
21331443
5.

Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.

Shi D, Zhan X, Yu X, Jia M, Zhang Y, Yao J, Hu X, Bao Z.

Lipids Health Dis. 2014 Nov 18;13:173. doi: 10.1186/1476-511X-13-173.

6.

Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.

Chang JH, Kato N, Muroyama R, Taniguchi H, Guleng B, Dharel N, Shao RX, Tateishi K, Jazag A, Kawabe T, Omata M.

Liver Int. 2010 Feb;30(2):311-8. doi: 10.1111/j.1478-3231.2009.02144.x. Epub 2009 Oct 16.

PMID:
19840259
7.

Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.

Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T.

Antiviral Res. 2017 Dec;148:5-14. doi: 10.1016/j.antiviral.2017.10.016. Epub 2017 Oct 23.

PMID:
29074218
8.

Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.

Saito K, Shirasago Y, Suzuki T, Aizaki H, Hanada K, Wakita T, Nishijima M, Fukasawa M.

J Virol. 2015 Feb;89(4):2220-32. doi: 10.1128/JVI.03385-14. Epub 2014 Dec 3.

9.

ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.

Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.

J Hepatol. 2011 Jul;55(1):11-8. doi: 10.1016/j.jhep.2010.10.017. Epub 2010 Nov 29.

PMID:
21145867
10.

Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

Liu Q, Bhat M, Bowen WD, Cheng J.

J Pharmacol Exp Ther. 2009 Dec;331(3):1062-70. doi: 10.1124/jpet.109.156216. Epub 2009 Sep 14.

11.

Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.

Wu HM, Yang YM, Kim SG.

Mol Pharmacol. 2011 Nov;80(5):859-69. doi: 10.1124/mol.111.072769. Epub 2011 Jul 29. Erratum in: Mol Pharmacol. 2012 Sep;82(3):561-2.

PMID:
21803969
13.

In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.

Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W 4th, Cheng G.

Antiviral Res. 2013 Nov;100(2):439-45. doi: 10.1016/j.antiviral.2013.08.018. Epub 2013 Sep 5.

PMID:
24013001
14.

RacGTPase-activating protein 1 interacts with hepatitis C virus polymerase NS5B to regulate viral replication.

Wu MJ, Ke PY, Horng JT.

Biochem Biophys Res Commun. 2014 Nov 7;454(1):19-24. doi: 10.1016/j.bbrc.2014.10.008. Epub 2014 Oct 8.

PMID:
25305482
15.

Relationships between hepatitis C virus replication and CXCL-8 production in vitro.

Koo BC, McPoland P, Wagoner JP, Kane OJ, Lohmann V, Polyak SJ.

J Virol. 2006 Aug;80(16):7885-93.

16.

Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.

Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, Kakinuma S, Oooka M, Azuma S, Tsuchiya K, Onogi H, Hagiwara M, Watanabe M.

Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86. doi: 10.1128/AAC.00113-10. Epub 2010 May 24.

17.

Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System.

Zhao F, Zhao T, Deng L, Lv D, Zhang X, Pan X, Xu J, Long G.

J Virol. 2017 Jan 3;91(2). pii: e01720-16. doi: 10.1128/JVI.01720-16. Print 2017 Jan 15.

18.

Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Kanda T, Steele R, Ray R, Ray RB.

J Virol. 2007 Jan;81(2):669-76. Epub 2006 Nov 1.

19.

Stearoyl coenzyme A desaturase 1 is associated with hepatitis C virus replication complex and regulates viral replication.

Nguyen LN, Lim YS, Pham LV, Shin HY, Kim YS, Hwang SB.

J Virol. 2014 Nov;88(21):12311-25. doi: 10.1128/JVI.01678-14. Epub 2014 Aug 13.

20.

Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Panigrahi R, Hazari S, Chandra S, Chandra PK, Datta S, Kurt R, Cameron CE, Huang Z, Zhang H, Garry RF, Balart LA, Dash S.

PLoS One. 2013 Aug 23;8(8):e72791. doi: 10.1371/journal.pone.0072791. eCollection 2013.

Supplemental Content

Support Center